Pages that link to "Q44601066"
Jump to navigation
Jump to search
The following pages link to Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients (Q44601066):
Displaying 50 items.
- Breast cancer chemoprevention: beyond tamoxifen (Q24793429) (← links)
- IGF status is altered by tamoxifen in patients with breast cancer. (Q28360503) (← links)
- Growth hormones and sex steroid interactions at puberty (Q30469459) (← links)
- Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer (Q33560280) (← links)
- Circulating IGF-I: New Perspectives for a New Century (Q33632902) (← links)
- Current status of tamoxifen use: An update for the surgical oncologist (Q33729025) (← links)
- Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. (Q33739214) (← links)
- Chemoprevention of breast cancer: the Italian experience. (Q33890132) (← links)
- Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer (Q33890560) (← links)
- Pancreatic cancer: a review of emerging therapies (Q33942341) (← links)
- IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion (Q33952555) (← links)
- Insulin-like growth factor physiology and cancer risk (Q33959681) (← links)
- The question of a link between insulin-like growth factor physiology and neoplasia (Q34030547) (← links)
- Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study (Q34065827) (← links)
- Mitogenic properties of insulin-like growth factors I and II, insulin-like growth factor binding protein-3 and epidermal growth factor on human breast epithelial cells in primary culture (Q34152247) (← links)
- Molecular and pharmacological aspects of antiestrogen resistance (Q34268841) (← links)
- Insulin-like growth factors and neoplasia. (Q34330521) (← links)
- Estrogens and selective estrogen receptor modulators in acromegaly (Q34541969) (← links)
- Chemoprevention for high-risk women: tamoxifen and beyond (Q34572541) (← links)
- Chemoprevention of breast cancer: implications for postmenopausal women (Q34585121) (← links)
- The R-Ras GTPase mediates cross talk between estrogen and insulin signaling in breast cancer cells (Q35071166) (← links)
- The potential autocrine/paracrine roles of ghrelin and its receptor in hormone-dependent cancer. (Q35090138) (← links)
- Biotherapeutic approaches to pancreatic cancer (Q35093628) (← links)
- Tamoxifen reduces serum insulin-like growth factor I (IGF-I) (Q35465195) (← links)
- Tamoxifen in axillary node--negative breast cancer: multisystem benefits and risks (Q35473061) (← links)
- Cellular effects of early exposure to sex hormones and antihormones (Q35507346) (← links)
- The insulin-like growth factor system in advanced breast cancer (Q35612304) (← links)
- Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone (Q35973711) (← links)
- Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone (Q36080730) (← links)
- Insulin-like growth factor 1 gene polymorphism and breast cancer risk among arab omani women: a case-control study (Q36111455) (← links)
- A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients (Q36136206) (← links)
- Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer (Q36138971) (← links)
- Does extra height justify a higher risk of breast cancer? (Q36214654) (← links)
- Plasma insulin-like growth factor in primary breast cancer patients treated with adjuvant chemotherapy (Q36292087) (← links)
- Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up (Q36295053) (← links)
- Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer (Q36618953) (← links)
- The association of breast mitogens with mammographic densities (Q36646178) (← links)
- Estrogens and aspects of prostate disease (Q36697811) (← links)
- Breast cancer of the older woman: an annotated review (Q36832390) (← links)
- Novel endocrine therapies in breast cancer (Q36859620) (← links)
- The potential role of somatostatin analogues in breast cancer treatment (Q36988009) (← links)
- IGF gene polymorphisms and breast cancer in African-American and Hispanic women (Q37095826) (← links)
- Does mammographic density reflect the expression of breast cancer markers? (Q38101685) (← links)
- Biocatalytic virus capsid as nanovehicle for enzymatic activation of Tamoxifen in tumor cells (Q40260796) (← links)
- Regulation of insulin-like growth factors by antiestrogen (Q40395035) (← links)
- The insulin-like growth factor system as a target in breast cancer (Q40396511) (← links)
- Molecular mechanisms of antiestrogen action in breast cancer (Q40644017) (← links)
- Insulin and estrogen receptor ligand influence the FGF-2 activities in MCF-7 breast cancer cells (Q40673081) (← links)
- An experimental model of diabetes and cancer in rats (Q40837370) (← links)
- Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine (Q40877335) (← links)